OBJECTIVE: To assess the role of antipseudomonal agents on Pseudomonas aeruginosa colonization and acquisition of resistance. DESIGN: Prospective cohort study. SETTING: Two medical intensive care units. PATIENTS AND PARTICIPANTS: 346 patients admitted for >or= 48 h. INTERVENTION: Analysis of data from an 8-month study comparing a mixing versus a cycling strategy of antibiotic use. MEASUREMENTS AND RESULTS: Surveillance cultures from nares, pharynx, rectum, and respiratory secretions were obtained thrice weekly. Acquisition of resistance was defined as the isolation, after 48 h of ICU stay, of an isolate resistant to a given antibiotic if culture of admission samples were either negative or positive for a susceptible isolate. Emergence of resistance refers to the conversion of a defined pulsotype from susceptible to non-susceptible. Forty-four (13%) patients acquired 52 strains of P. aeruginosa. Administration of piperacillin-tazobactam for >or= 3 days (OR 2.6, 95% CI 1.09-6.27) and use of amikacin for >or= 3 days (OR 2.6, 95% CI 1.04-6.7) were positively associated with acquisition of P. aeruginosa, whereas use of quinolones (OR 0.27, 95% CI 0.1-0.7) and antipseudomonal cephalosporins (OR 0.27, 95% CI 0.08-0.9) was protective. Exposure to quinolones and cephalosporins was not associated with the acquisition of resistance, whereas it was linked with usage of all other agents. Neither quinolones nor cephalosporins were a major determinant on the emergence of resistance to themselves, as resistance to these antibiotics developed at a similar frequency in non-exposed patients. CONCLUSIONS: In critically ill patients, quinolones and antipseudomonal cephalosporins may prevent the acquisition of P. aeruginosa and may have a negligible influence on the acquisition and emergence of resistance.
OBJECTIVE: To assess the role of antipseudomonal agents on Pseudomonas aeruginosa colonization and acquisition of resistance. DESIGN: Prospective cohort study. SETTING: Two medical intensive care units. PATIENTS AND PARTICIPANTS: 346 patients admitted for >or= 48 h. INTERVENTION: Analysis of data from an 8-month study comparing a mixing versus a cycling strategy of antibiotic use. MEASUREMENTS AND RESULTS: Surveillance cultures from nares, pharynx, rectum, and respiratory secretions were obtained thrice weekly. Acquisition of resistance was defined as the isolation, after 48 h of ICU stay, of an isolate resistant to a given antibiotic if culture of admission samples were either negative or positive for a susceptible isolate. Emergence of resistance refers to the conversion of a defined pulsotype from susceptible to non-susceptible. Forty-four (13%) patients acquired 52 strains of P. aeruginosa. Administration of piperacillin-tazobactam for >or= 3 days (OR 2.6, 95% CI 1.09-6.27) and use of amikacin for >or= 3 days (OR 2.6, 95% CI 1.04-6.7) were positively associated with acquisition of P. aeruginosa, whereas use of quinolones (OR 0.27, 95% CI 0.1-0.7) and antipseudomonal cephalosporins (OR 0.27, 95% CI 0.08-0.9) was protective. Exposure to quinolones and cephalosporins was not associated with the acquisition of resistance, whereas it was linked with usage of all other agents. Neither quinolones nor cephalosporins were a major determinant on the emergence of resistance to themselves, as resistance to these antibiotics developed at a similar frequency in non-exposed patients. CONCLUSIONS: In critically ill patients, quinolones and antipseudomonal cephalosporins may prevent the acquisition of P. aeruginosa and may have a negligible influence on the acquisition and emergence of resistance.
Authors: D Lepelletier; N Caroff; D Riochet; P Bizouarn; A Bourdeau; F Le Gallou; E Espaze; A Reynaud; H Richet Journal: Eur J Clin Microbiol Infect Dis Date: 2006-09 Impact factor: 3.267
Authors: Anthony D Harris; David Smith; Judith A Johnson; Douglas D Bradham; Mary-Claire Roghmann Journal: Clin Infect Dis Date: 2001-12-26 Impact factor: 9.079
Authors: M P Fink; D R Snydman; M S Niederman; K V Leeper; R H Johnson; S O Heard; R G Wunderink; J W Caldwell; J J Schentag; G A Siami Journal: Antimicrob Agents Chemother Date: 1994-03 Impact factor: 5.191
Authors: G Zanetti; F Bally; G Greub; J Garbino; T Kinge; D Lew; J-A Romand; J Bille; D Aymon; L Stratchounski; L Krawczyk; E Rubinstein; M-D Schaller; R Chiolero; M-P Glauser; A Cometta Journal: Antimicrob Agents Chemother Date: 2003-11 Impact factor: 5.191
Authors: C Peña; A Guzmán; C Suarez; M A Dominguez; F Tubau; M Pujol; F Gudiol; J Ariza Journal: Antimicrob Agents Chemother Date: 2007-04-09 Impact factor: 5.191
Authors: M Montero; M Sala; M Riu; F Belvis; M Salvado; S Grau; J P Horcajada; F Alvarez-Lerma; R Terradas; M Orozco-Levi; X Castells; H Knobel Journal: Eur J Clin Microbiol Infect Dis Date: 2009-12-24 Impact factor: 3.267
Authors: K de With; F Allerberger; S Amann; P Apfalter; H-R Brodt; T Eckmanns; M Fellhauer; H K Geiss; O Janata; R Krause; S Lemmen; E Meyer; H Mittermayer; U Porsche; E Presterl; S Reuter; B Sinha; R Strauß; A Wechsler-Fördös; C Wenisch; W V Kern Journal: Infection Date: 2016-06 Impact factor: 3.553
Authors: Silvia Gómez-Zorrilla; Mariana Camoez; Fe Tubau; Elisabet Periche; Rosario Cañizares; M Angeles Dominguez; Javier Ariza; Carmen Peña Journal: Antimicrob Agents Chemother Date: 2014-07-21 Impact factor: 5.191
Authors: N Cobos-Trigueros; M Rinaudo; M Solé; P Castro; J Pumarol; C Hernández; S Fernández; J M Nicolás; J Mallolas; J Vila; L Morata; J M Gatell; A Soriano; J Mensa; J A Martínez Journal: Eur J Clin Microbiol Infect Dis Date: 2013-10-23 Impact factor: 3.267
Authors: Anne F Voor In 't Holt; Juliëtte A Severin; Emmanuel M E H Lesaffre; Margreet C Vos Journal: Antimicrob Agents Chemother Date: 2014-02-18 Impact factor: 5.191
Authors: Y M Zou; Y Ma; J H Liu; J Shi; T Fan; Y Y Shan; H P Yao; Y L Dong Journal: Eur J Clin Microbiol Infect Dis Date: 2014-12-10 Impact factor: 3.267
Authors: Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Jerôme Pugin; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2010-01-08 Impact factor: 17.440
Authors: Nazaret Cobos-Trigueros; Mar Solé; Pedro Castro; Jorge Luis Torres; Cristina Hernández; Mariano Rinaudo; Sara Fernández; Álex Soriano; José María Nicolás; Josep Mensa; Jordi Vila; José Antonio Martínez Journal: Crit Care Date: 2015-05-04 Impact factor: 9.097